Int J Biol Sci 2022; 18(10):3944-3960. doi:10.7150/ijbs.70889 This issue Cite

Research Paper

CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression

Hang Peng1, Wan Zhang1, Huanhuan Dong1, Jialan Yuan1, Yankun Li1, Fanni Li2, Daping Yu3✉, Yingjie Guan4✉, Feng Zhang1✉

1. Bone and Joint Research Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
2. Department of Talent Highland, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
3. Second Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
4. Department of Medicine, Rhode Island Hospital, Providence, RI 02903, USA.

Citation:
Peng H, Zhang W, Dong H, Yuan J, Li Y, Li F, Yu D, Guan Y, Zhang F. CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression. Int J Biol Sci 2022; 18(10):3944-3960. doi:10.7150/ijbs.70889. https://www.ijbs.com/v18p3944.htm
Other styles

File import instruction

Abstract

Graphic abstract

Our understanding of coding gene functions in lung cancer leads to the development of multiple generations of targeted drugs. Noncoding RNAs, including circular RNAs (circRNAs), have been demonstrated to play a vital role in tumorigenesis. Uncovering the functions of circRNAs in tumorigenesis and their underlying regulatory mechanisms may shed new light on the development of novel diagnostic and therapeutic strategies for human cancer. Here we report the important role of circFAT1 in lung adenocarcinoma (LUAD) progression and the potential impact of circFAT1 on LUAD treatment. We found that circFAT1 was one of the top expressed circRNAs in A549 cells by circRNA-seq and was significantly upregulated in human LUAD tissues. Multiple cellular assays with A549 and PC9 LAUD cell lines under both gain-of-function and loss-of-function conditions demonstrated that circFAT1 promoted proliferation of LUAD cells in vitro and in vivo. At molecular level, circFAT1 sequestered miR-7 to upregulate IRS2, which in turn regulated downstream ERK1/2 phosphorylation and CCND1 expression, ultimately promoting tumor progression. In addition, we showed that DDP treatment was much more effective in circFAT1 knockdown tumor cells in vitro and in a xenograft tumor model. Our results indicate that circFAT1 promote tumorigenesis in LUAD through sequestering miR-7, consequently upregulating IRS2-ERK1/2-mediated CCND1 expression, and can be a valuable therapeutic target and an important parameter for precision treatment in LUAD patients.

Keywords: circFAT1, miR-7-5p, IRS2, LUAD, DDP


Citation styles

APA
Peng, H., Zhang, W., Dong, H., Yuan, J., Li, Y., Li, F., Yu, D., Guan, Y., Zhang, F. (2022). CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression. International Journal of Biological Sciences, 18(10), 3944-3960. https://doi.org/10.7150/ijbs.70889.

ACS
Peng, H.; Zhang, W.; Dong, H.; Yuan, J.; Li, Y.; Li, F.; Yu, D.; Guan, Y.; Zhang, F. CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression. Int. J. Biol. Sci. 2022, 18 (10), 3944-3960. DOI: 10.7150/ijbs.70889.

NLM
Peng H, Zhang W, Dong H, Yuan J, Li Y, Li F, Yu D, Guan Y, Zhang F. CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression. Int J Biol Sci 2022; 18(10):3944-3960. doi:10.7150/ijbs.70889. https://www.ijbs.com/v18p3944.htm

CSE
Peng H, Zhang W, Dong H, Yuan J, Li Y, Li F, Yu D, Guan Y, Zhang F. 2022. CircFAT1 Promotes Lung Adenocarcinoma Progression by Sequestering miR-7 from Repressing IRS2-ERK-mediated CCND1 Expression. Int J Biol Sci. 18(10):3944-3960.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.